Cytokinetics, Incorporated — Income Charts
8 quarters of history · ending 2025-12-31 · SEC EDGAR
Source:10-K · 10-Q
Revenue, Gross Profit, Operating Income & Net Income
Margin (%)
Operating Expenses
Income Breakdown
Revenue↑+4.9% +$828K
$18M
R&D↑+11.5% +$11M
$104M
D&A↑+20.1% +$478K
$3M
Operating Income↓-18.4% -$26M
$-167M
EBITDA↑+20.1% +$478K
$3M
Interest Expense↑+59.7% +$5M
$14M
Interest Income
—
Other Income/Expense
—
Pretax Income
—
Tax Provision
$0
Net Income↓-90.7% -$146M
$-306M
Operating Margin↑+21797.2pts
-8613.4%
Net Margin↑+18860.0pts
-15815.0%
Effective Tax Rate
—
ETR (Continuing Operations)↑+0.0pts
0.0%
ETR Federal Statutory↑+0.0pts
21.0%
ETR State + Local (pp)↑+0.0pts
0.0%
ETR Foreign Differential (pp)↑+0.0pts
0.0%
Operating Lease Cost
—
Revenue YoY Variation↓-907.5pts
4.9%
Income YoY Variation↓-3.3pts
-18.4%
Revenue QoQ Variation↓-2738.8pts
817.1%
Income QoQ Variation↓-41.4pts
-49.5%